Skip to main content
Evidence Snapshot

Peptidoglycan D,D-transpeptidase MrdA

CHEMBL2354313 SINGLE PROTEIN Bacteria
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T10:06:17Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2354313
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Peptidoglycan D,D-transpeptidase MrdA as ChEMBL target CHEMBL2354313, mapped to UniProt P0AD65. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Peptidoglycan D,D-transpeptidase MrdA
SINGLE PROTEIN · Bacteria
As of 2026-09-13
ChEMBL target ID
CHEMBL2354313
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P0AD65
Peptidoglycan D,D-transpeptidase MrdA
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Peptidoglycan D,D-transpeptidase MrdA matters

As of 2026-09-13

Peptidoglycan D,D-transpeptidase MrdA is reviewed as Peptidoglycan D,D-transpeptidase MrdA (UniProt P0AD65); Peptidoglycan D,D-transpeptidase MrdA shows approved-linked disease relevance led by bacterial disease. 1 more disease program remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded..

Protein context
Peptidoglycan D,D-transpeptidase MrdA

Peptidoglycan D,D-transpeptidase MrdA Sequence length is 633 aa.

Review this target as Peptidoglycan D,D-transpeptidase MrdA, mapped to UniProt P0AD65. Sequence length is 633 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt P0AD65 Protein
Disease context
bacterial disease

Peptidoglycan D,D-transpeptidase MrdA shows approved-linked disease relevance led by bacterial disease. 1 more disease program remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 1 additional disease programs remain visible in the same card. Linked drugs include AMDINOCILLIN, AMDINOCILLIN PIVOXIL.

Start review with bacterial disease because it currently carries approved-linked support. Linked drugs include AMDINOCILLIN, AMDINOCILLIN PIVOXIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 2 linked drugs
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Peptidoglycan D,D-transpeptidase MrdA matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P0AD65, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why bacterial disease is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

0
Total Compounds
0
Total Assays
0
Approved Drugs
-
Activity Types

pChEMBL Activity Distribution

← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T10:06:17Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2354313